Involvement of the P2X7 receptor in the migration and metastasis of tamoxifen-resistant breast cancer: effects on small extracellular vesicles production

  • Sci Rep. 2019 Aug 12;9(1):11587. doi: 10.1038/s41598-019-47734-z.
Miso Park  1 Jieun Kim  1 Nguyen T T Phuong  1 Jung Gyu Park  1 Jin-Hee Park  2 Yong-Chul Kim  2 Moon Chang Baek  3 Sung Chul Lim  4 Keon Wook Kang  5
Affiliations
  • 1. College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, 08826, Republic of Korea.
  • 2. School of Life Sciences, Gwangju Institute of Science & Technology, Gwangju, 61005, Republic of Korea.
  • 3. Department of Biochemistry, School of Medicine, Kyungpook National University, Daegu, 41944, Republic of Korea.
  • 4. Department of Pathology, College of Medicine, Chosun University, Gwangju, 61452, Republic of Korea.
  • 5. College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, 08826, Republic of Korea. [email protected].
Abstract

Tamoxifen (TAM) is the standard anti-hormonal therapy for estrogen receptor-positive breast Cancer. However, long-term TAM therapy can make acquisition of TAM resistance and there are still no solutions to treat TAM-resistant breast Cancer. In this study, we found that protein and mRNA expression of the P2X purinoreceptor 7 (P2X7) was higher in tamoxifen resistant MCF-7 (TAMR-MCF-7) cells than in control MCF-7 cells. P2X7 inhibition potently inhibited the migration of TAMR-MCF-7 cells and the liver metastasis burden of TAMR-MCF-7 cells in the spleen-liver metastasis experiment. However, the P2X7 antagonist did not affect protein expression of matrix metalloproteinase (MMP)-2, MMP-9, and epithelial-mesenchymal transition markers. Here our data indicate a link between small extracellular vesicles (sEV) and P2X7, and suggest a new mechanism of metastasis in TAM-resistant breast Cancer cells through P2X7 receptors. The migration of TAMR-MCF-7 cells was increased in a concentration-dependent manner by purified sEV treatment. The number of secreted sEVs and the protein levels of CD63 in TAMR-MCF-7 cells were decreased by the P2X7 antagonist, showing that P2X7 influences the production of sEV. Our results suggest that inhibiting the P2X7 could be considered for metastasis prevention in TAM-resistant Cancer patients.

Products